Leerink Partners analyst Andrew Berens reiterated a Buy rating on Cullinan Management (CGEM – Research Report) yesterday and set a price target ...

New in vitro preclinical data show CLN-978 induced similar T cell activation, target B cell depletion, and cytokine production in human peripheral blood mononuclear cells (PBMC) derived from ...

Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune ...

(MENAFN- GlobeNewsWire - Nasdaq) Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan ...

Cullinan will also have a Booth (#2304) in the Exhibit Hall. New in vitro preclinical data show CLN-978 induced similar T cell activation, target B cell depletion, and cytokine production in human ...

Cullinan Therapeutics (CGEM) will present new preclinical data for CLN-978, its novel CD19xCD3 T cell engager. These data and the study schema for a planned Phase 1b study in patients with ...

Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, will present new preclinical data ...

New in vitro preclinical data show CLN-978 induced similar T cell activation, target B cell depletion, and cytokine production in human peripheral blood mononuclear cells (PBMC) derived from patients ...

Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted ...

CAMBRIDGE, Mass. - Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company, has announced the initiation of a global Phase 1b clinical trial for CLN-978, a novel T cell engager ...